Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 11, 1997, Pages 789-796

  Garau, J ^a   Blanquer, J ^b   Cobo, L ^c   Corcia, S ^d   Daguerre, M ^e   De Latorre, F J ^f   Leon, C ^g   Del Nogal, F ^h   Net, A ⁱ   Rello, J ^j  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d Hospital Clinico Universitario   (Spain)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h HOSPITAL SEVERO OCHOA   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CILASTATIN; CILASTATIN PLUS IMIPENEM; IMIPENEM; MEROPENEM;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; APNEA; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HOSPITAL INFECTION; HUMAN; HYPERBILIRUBINEMIA; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCYTOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SEIZURE; SEPTICEMIA; SHOCK; SKIN INFECTION; THROMBOCYTHEMIA; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VASCULITIS;

EID: 15444357986     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01700407     Document Type: Article

References (23)

1. Vincent J-L, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin M-H, Wolff M, Spencer RC, Hemmer M, for the EPIC International Advisory Committee: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. Journal of the American Medical Association 1995, 274: 639-644.
2. Fagon J-Y, Chastre J, Vuagnat A, Trouillet J-L, Novara A, Gibert C: Nosocomial pneumonia and mortality among patients in intensive care units. Journal of the American Medical Association 1996, 275: 866-869.
3. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ: The pharmacokinetics of meropenem in volunteers. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 311-320.
4. Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR: Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. European Journal of Clinical Microbiology & Infectious Diseases 1991, 10: 85-88.
5. Fukasawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki T: Stability of meropenem and the effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase-l. Antimicrobial Agents and Chemotherapy 1992, 36: 1577-1579.
6. Birnbaum J, Kahan FM, Kropp H, Macdonald S: Carbapenems, a new class of β-lactam antibiotics. Discovery and development of imipenem/cilastatin. American Journal of Medicine 1985, 78, Supplement 6A: 3-21.
7. Jones RN, Barry AL, Thornsberry C: In-vitro studies of meropenem. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 9-29.
8. Moellering RC, Eliopoulos GM, Sentochnik DE: The carbapenems: new broad spectrum β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 1-7.
9. Edwards JR, Turner PJ: Laboratory data which differentiate meropenem and imipenem. Scandinavian Journal of Infectious Diseases 1995, Supplement 96: 5-10.
10. Sirot D: Extended-spectrum plasmid-mediated β-lactamases: Journal of Antimicrobial Chemotherapy 1995, 36, Supplement A. 19-34.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Critical Care Medicine 1985, 13: 818-829.
12. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A4. NCCLS, Villanova, PA, 1990.
13. Fleiss JL: Statistical methods for rates and proportions. John Wiley & Sons, New York, 1981, p. 161-165.
14. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken J, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MR and the International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne Dell' Adulto Infection Program: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 1996, 40: 1108-1115.
15. Mouton YJ, Beuscart C, Meropenem Study Group: Empirical monotherapy with meropenem in serious bacterial infections. Journal of Antimicrobial Chemotherapy 1995, 36, Supplement A: 145-156.
16. Condon RE, Walker AP, Sirinek KR, White PW, Fabian TC, Nichols RL, Wilson SE: Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clinical Infectious Diseases 1995, 21: 544-550.
17. Colardyn F, Faulkner KL, for the Meropenem Serious Infection Study Group: Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Journal of Antimicrobial Chemotherapy 1996, 38: 523-537.
18. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H: Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. American Journal of Medicine 1988, 84: 911-918.
19. Patel JB, Giles RE: Meropenem: evidence of lack of proconvulsive tendency in mice. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 307-309.
20. De Sarro A, Ammendola D, Zappala M, Grasso S, De Sarro GB: Relationship between structure and convulsant properties of some β-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrobial Agents and Chemotherapy 1995, 39: 232-237.
21. Norrby SR, Newell PA, Faulkner KL, Lesky W: Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. Journal of Antimicrobial Chemotherapy 1995, 36, Supplement A: 207-223.
22. Klugman KP, Dagan R, and the Meropenem Meningitis Study Group: A randomised comparison of meropenem with cefotaxime for the treatment of bacterial meningitis. Antimicrobial Agents and Chemotherapy 1995, 39: 1140-1146.
23. Schmutzhard E, Williams KJ, Vukmirovits G, Chmelik V, Pfausler B, Featherstone A, and the Meropenem Meningitis Study Group: A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of meningitis in adults. Journal of Antimicrobial Chemotherapy 1995, 36, Supplement A: 85-98.